OncoMatch/Clinical Trials/NCT04621435
Imaging of Solid Tumors Using FAP-2286
Is NCT04621435 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Gallium-68 labelled (68Ga-) FAP-2286 and Copper-64 labeled (64Cu-) FAP-2286 for solid tumors, adult.
Treatment: Gallium-68 labelled (68Ga-) FAP-2286 · Copper-64 labeled (64Cu-) FAP-2286 — This is a multi-arm prospective trial that evaluates the ability of a novel imaging radiolabeled agents to detect metastatic cancer in participants with solid tumors using a gallium 68 (68Ga-) or copper 64 (64Cu-) FAP-2286 tracer. FAP-2286 is a peptidomimetic molecule that that binds to Fibroblast Activation Protein (FAP). FAP is a transmembrane protein expressed on cancer-associated fibroblasts, and has been shown to be present on a number of solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Disease stage
Metastatic disease required
Metastatic Cancer
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Francisco · San Francisco, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify